Aesica Meets New Serialization Requirements With A QAD ERP Upgrade

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SANTA BARBARA, Calif.--(BUSINESS WIRE)--QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB), a leading provider of enterprise software and services, announced today that Aesica Pharmaceuticals S.r.l., the Italian division of Aesica Pharmaceuticals Limited, has upgraded to QAD Enterprise Applications Enterprise Edition (QAD EE). The upgrade helped Aesica meet the deadline for a new serialization regulation for the Chinese market. A recently published case study shares the complete details of the implementation and its benefits.

Aesica is a leading pharmaceutical contract development and manufacturing organization (CDMO). The company, operating in a highly regulated industry, had to meet product serialization and tracking regulations to maintain customer safety, while fighting drug counterfeiting, streamlining the recall process and minimizing financial loss.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC